central nervous system infection, encephalitis, meningitis
Conditions
Interventions
We use the remaining 200 micro L of the cerebrospinal fluid with written, informed consent from patient or patients'
parents between January 2020 and March 2021. We perform molecular meningitis/encephalitis panel test to identify the causative organism within 72 hours. The results of tests will be disclosed to the
s general condition, and other test results.
Sponsors
Hyogo Prefectural Kobe Children's Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients admitted to our institution due to fever, disturbance of consciousness, or convulsions, who were suspected of meningitis or acute encephalitis and underwent a HSV-DNA test of cerebrospinal fluid using high-sensitivity PCR
Exclusion criteria
Exclusion criteria: Patients who have solid tumors, hematologic malignancies, primary immunodeficiency, cystic fibromatosis as underlying diseases Patients who are treated with long-term steroids or immunosuppressants Patients who could not be performed molecular meningitis/encephalitis panel test within 72 hours after collection of CSF specimen. Patients who have not given consent to sample collection and study from the patient or the patients' parents
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Duration of use of acyclovir for subjects | — |
Countries
Japan
Contacts
Public ContactShogo Otake
Hyogo Prefectural Kobe Children's Hospital Division of Infectious Disease
Outcome results
None listed